Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: Preclinical in vivo characterization

Investigative Radiology

Volumn 37, Issue 4, 2002, Pages 167-177

  Wagner, Susanne ^a   Schnorr, Jörg ^a   Pilgrimm, Herbert ^b   Hamm, Bernd ^a   Taupitz, Matthias ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Ferropharm GmbH   (Germany)

Author keywords

Contrast media; Iron oxide particles; Magnetic resonance angiography; MR imaging; Preclinical studies

Indexed keywords

CITRIC ACID; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTOXICITY; IN VIVO STUDY; LETHAL DOSE; LIVER FUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MOLECULAR SIZE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SWINE; VASCULARIZATION;

EID: 0036201973     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200204000-00002     Document Type: Article

References (46)

1. Ferrite particles: A new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration
2. Ferrite particles: A superparamagnetic MR contrast agent for the reticuloendothelial system
3. Superparamagnetic iron oxide: Clinical application as a contrast agent for MR imaging of the liver
4. Superparamagnetic iron oxide: Enhanced detection of focal splenic tumors with MR imaging
5. Ultrasmall superparamagnetic iron oxide: An intravenous contrast agent for assessing lymph nodes with MR imaging
6. Intravenous MR lymphography with superparamagnetic iron oxide particles: Experimental studies in rats and rabbits
7. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: Radiographic-pathologic correlation
8. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent
9. Superparamagnetic nanoparticles as blood-pool contrast agents. Contribution to MRI preclinical investigations
10. Pulmonary MR angiography with ultrasmall superparamagnetic iron oxide particles as a blood pool agent and a navigator echo for respiratory gating: Pilot study
11. 'NC100150', a preparation of iron oxide nanoparticles ideal for positive-contrast MR angiography
12. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography
13. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits
14. Detection of experimental hepatic tumors using long circulating superparamagnetic particles
15. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A
16. Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation
17. Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities
18. Phase I clinical evaluation of a new iron oxide MR contrast agent
19. Coronary MR angiography: Experimental results with a monomer-stabilized blood pool contrast medium
20. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: Preclinical results in rats and rabbits
21. Identifying environmental chemicals causing mutations and cancer
22. Revised methods for the Salmonella mutagenicity test
23. The micronucleus test. Methodological aspects
24. Gadolinium-enhanced magnetic resonance angiography of abdominal aortic aneurysms
25. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography
26. Magnetic resonance angiography with gadomer-17. An animal study original investigation
27. A new polysaccharide macromolecular contrast agent for MR imaging: Biodistribution and imaging characteristics
28. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool and perfusion imaging
29. Gd-DTPA-polylysine-enhanced pulmonary time-of-flight MR angiography
30. A new macromolecule as a contrast agent for MR angiography: Preparation, properties, and animal studies
31. Dendrimer-based metal chelates: A new class of magnetic resonance imaging contrast agents
32. MS-325: Albumin-targeted contrast agent for MR angiography
33. Contrast agent-enhanced, free-breathing, three-dimensional coronary magnetic resonance angiography
34. Three-dimensional MRI of coronary arteries using an intravascular contrast agent
35. Application of superparamagnetic iron oxide (AMI-227) for 3D phase-contrast MR angiography
36. Frequency dependence of MR relaxation times. II. Iron oxides
37. Age-related blood half-life of particulate contrast material: Experimental results with a USPIO in rats
38. Benefit of T1 reduction for magnetic resonance coronary angiography: A numerical simulation and phantom study
39. Contrast-enhanced MR. imaging of coronary arteries: Comparison of intra- and extravascular contrast agents in swine
40. Superparamagnetic iron oxide: Pharmacokinetics and toxicity
41. MION-ASF: Biokinetics of an MR receptor agent
42. Pulmonary intravascular macrophages: Their contribution to the mononuclear phagocyte system in 13 species
43. Prevention of the hemodynamic effects of iopromide-carrying liposomes in rats and pigs
44. Contrast-enhanced 3D-TOF MRA of peripheral vessels: Intravascular versus extracellular MR contrast media